The Food and Drug Administration (FDA) is withdrawing the approval of abbreviated new drug application (ANDA) 075726 for PEMOLINE Tablets, 18.75 milligrams (mg), 37.5 mg, and 75 mg, held by Mallinkrodt Pharmaceuticals, LLC (Mallinkrodt). Mallinkrodt requested withdrawal of this application and has waived its opportunity for a hearing.
Document
Mallinkrodt Pharmaceuticals LLC; Withdrawal of Approval of an Abbreviated New Drug Application for PEMOLINE Tablets, 18.75 Milligrams, 37.5 Milligrams, and 75 Milligrams
The Food and Drug Administration (FDA) is withdrawing the approval of abbreviated new drug application (ANDA) 075726 for PEMOLINE Tablets, 18.75 milligrams (mg), 37.5 mg, and 75...
Legal Citation
Federal Register Citation
Use this for formal legal and research references to the published document.
83 FR 6192
Web Citation
Suggested Web Citation
Use this when citing the archival web version of the document.
“Mallinkrodt Pharmaceuticals LLC; Withdrawal of Approval of an Abbreviated New Drug Application for PEMOLINE Tablets, 18.75 Milligrams, 37.5 Milligrams, and 75 Milligrams,” thefederalregister.org (February 13, 2018), https://thefederalregister.org/documents/2018-02925/mallinkrodt-pharmaceuticals-llc-withdrawal-of-approval-of-an-abbreviated-new-drug-application-for-pemoline-tablets-18-75.